Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829678 | 1.00 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3BRD4CREBBP | |
| SCHEMBL5829744 | 0.95 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3BRD4CREBBP | |
| SCHEMBL5829742 | 0.95 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3BRD4CREBBP | |
| SCHEMBL5829756 | 0.86 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL5829760 | 0.86 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL1021480 | 0.83 | SLC6A3 (0.68) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1021477 | 0.83 | SLC6A3 (0.68) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL1023145 | 0.82 | SLC6A3 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6553255 | 0.80 | SLC6A4 (0.56) | SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL5829797 | 0.80 | SLC6A4 (0.56) | SLC6A2SLC6A4SLC6A3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045522-B2 | 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field | NEUROSEARCH A/S (DK) | 2006-05-16 | — | — | US | claimed |
| US-20040116703-A1 | 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field | NEUROSEARCH A/S | 2004-06-17 | — | — | US | claimed |
| EP-1382605-A2 | 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands | NEUROSEARCH A/S (DK) | 2004-01-21 | — | — | EP | claimed |
| US-20020035122-A1 | 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives | ANIONA APS (DK) | 2002-03-21 | — | — | US | claimed |
| US-7045522-B2 | 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field | NEUROSEARCH A/S (DK) | 2006-05-16 | — | — | US | disclosed |
| US-20040116703-A1 | 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field | NEUROSEARCH A/S | 2004-06-17 | — | — | US | disclosed |
| EP-1382605-A2 | 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands | NEUROSEARCH A/S (DK) | 2004-01-21 | — | — | EP | disclosed |
| US-6680328-B2 | CHOLINERGIC LIGANDS OF NICOTINIC ACETYL CHOLINE RECEPTORS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, SMOOTH MUSCLE CONTRACTION DISORDERS, ENDOCRINE DISEASES/DISORDERS, NEURODEGENERATION, INFLAMMATION, PAIN, AND DRUG WITHDRAWAL | NEUROSEARCH A/S (DK) | 2004-01-20 | — | — | US | disclosed |
| US-20020035122-A1 | 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives | ANIONA APS (DK) | 2002-03-21 | — | — | US | disclosed |
| EP-1133494-A1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH A/S (DK) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000032600-A1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035122-A1 | 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives | CHRNA2, CHRNA7, CHRNA10 | SLC6A2 589/4885SLC6A4 1439/4885SLC6A3 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.